January 10th 2025
Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, meeting the primary end point of the phase 3 NIVOPOSTOP trial.
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
COSMIC-311 Update: Cabozantinib Sustains PFS Benefit After 10 Months in RAI-DTC
October 29th 2021Extended follow-up of patients in COSMIC-311 showed continued survival benefit and tumor reduction with cabozantinib versus placebo in patients with radioactive iodine-refractory differentiated thyroid cancer.
Read More
Clinical Benefit of Cabozantinib Not Impacted by Age in Patients With RAI-Refractory DTC
October 7th 2021A subgroup analysis of the phase 3 COSMIC-311 study revealed no key differences in the survival and responses observed with cabozantinib based on the age of patients with RAI-refractory differentiated thyroid cancer.
Read More
Larotrectinib and The Risk of Fracture in TRK Fusion Thyroid Cancer
September 29th 2021Theodore W. Laetsch, MD, an attending physician with the Cancer Center at Children’s hospital of Philadelphia discusses if there is an increased risk of fractures with larotrectinib in patients with TRK fusion positive thyroid cancer.
Read More
BRAF/MEK Inhibitor Combination Shows Promise in Anaplastic Thyroid Cancer
September 28th 2021Principle study investigator Yuliya Mikheeva, MD, PhD, of Saint-Petersburg State University, discussed the combination of dabrafenib and trametinib for the treatment of anaplastic thyroid cancer in an interview with Targeted Oncology.
Read More